primidins modified in position-5

专利摘要:
PRIMIDINS MODIFIED IN POSITION-5 AND ITS USE. The present invention relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines, as well as phosphoramidite and triphosphate derivatives thereof. The present disclosure also relates to methods of making and using them.
公开号:BR112012025872B1
申请号:R112012025872-9
申请日:2011-04-12
公开日:2021-04-20
发明作者:John Rohloff；Nebojsa Janjic；Jeffrey D. Carter；Catherine Fowler
申请人:Somalogic, Inc.；
IPC主号:

专利说明:

RELATED ORDERS
[001] This application claims the benefit of Provisional Application US 61/323,145, filed April 12, 2010, which is incorporated herein by reference in its entirety. FIELD OF THE INVENTION
[002] The present invention relates to the field of nucleic acid chemistry, specifically to uridines modified in position 5, as well as phosphoramidides and triphosphate derivatives thereof. The present disclosure also refers to methods of making and using them. The disclosure includes the use of modified nucleosides as part of an oligonucleotide or an aptamer. BACKGROUND
[003] The following description provides a summary of information relevant to the present disclosure and is not an admission that any information provided or publications mentioned herein are prior art to the present disclosure.
[004] There has been considerable interest in the development of modified nucleosides as therapeutic agents, diagnostic agents and for incorporation into oligonucleotides. For example, modified nucleosides such as AZT, ddI, d4T and others have been used to treat AIDS. 5-trifluoromethyl-2'-deoxyuridine is active against herpetic keratitis and 5-iodo-1-(2-deoxy-2-fluoro-bD-arabinofuranosyl)cytosine has activity against CMV, VZV, HSV-1, HSV-2 and EBV (A Textbook of Drug Design and Development, Povl Krogsgaard-Larsen and Hans Bundgaard, Eds., Harwood Academic Publishers, 1991, Chapter 15).
[005] Modified nucleosides have shown utility in diagnostic applications. In these applications, nucleosides are incorporated into DNA at determinable locations and various diagnostic methods are used to determine the location of the modified nucleosides. These methods include radiolabeling, fluorescent labeling, biotinylation and tape cleavage. An example of strand cleavage involves reacting the nucleoside with hydrazine to provide urea nucleosides, then reacting the urea nucleoside with piperidine to cause strand cleavage (the Maxam-Gilbert method).
[006] Modified nucleosides have also been incorporated into oligonucleotides. There are several ways in which oligonucleotides can be useful as therapeutics. Antisense oligonucleotides can bind to certain genetic coding regions in an organism to prevent protein expression or block various cellular functions. In addition, a process known as the SELEX process or Systematic Evolution of Ligands for EXponential Enrichment allows us to identify and produce oligonucleotides (referred to as "aptamers") that selectively bind to target molecules. The SELEX process is described in U.S. Pat. No. 5,270,163, the contents of which are incorporated herein by reference.
[007] The SELEX method involves selecting oligonucleotides from a mixture of candidates to obtain virtually any desired criteria of affinity and binding selectivity. Starting from a random mixture of oligonucleotides, the method involves contacting the mixture with a target under conditions favorable for binding (or interaction), splitting unbound oligonucleotides from oligonucleotides which have bound to (or interacted with) target molecules , dissociating the target oligonucleotide pairs, amplifying the dissociated oligonucleotides from the target oligonucleotide pairs to provide a ligand-enriched oligonucleotide mixture, then repeating the ligation, splitting, dissociating and amplifying steps through as many cycles as desired .
[008] Modified nucleosides can be incorporated into antisense oligonucleotides, ribozymes and oligonucleotides used in or identified through the SELEX process. These nucleosides can confer in vivo and in vitro stability of oligonucleotides to endo and exonucleases, alter the charge, hydrophilicity or lipophilicity of the molecule and/or confer differences in three-dimensional structure.
[009] Nucleoside modifications that have been previously described include sugar modifications at position 2', pyrimidine modifications at position 5, purine modifications at position 8, modifications to exocyclic amines, 4-thiouridine substitution, 5-substitution bromine or 5-iodo-uracil, major part modifications and methylations. Modifications have also included 3' and 5' modifications, such as capping. PCT WO 91/14696, incorporated herein by reference, describes a method for chemically modifying antisense oligonucleotides to enhance entry into a cell.
[010] US Patents 5,428,149, 5,591,843, 5,633,361, 5,719,273 and 5,945,527, which are incorporated herein by reference in their entirety, describe modification of pyrimidine nucleosides via palladium coupling reactions. In some embodiments, a nucleophile and carbon monoxide are coupled to pyrimidine nucleosides containing a conducting group on the 5-position of the pyrimidine ring, preferably forming ester and amide derivatives.
[011] A variety of methods have been used to make oligonucleotides resistant to degradation by exonucleases. PCT WO 90/15065 describes a method for producing exonuclease resistant oligonucleotides by incorporating two or more phosphoramidite, phosphoromonothionate and/or phosphorodithionate at the 5' and/or 3' ends of the oligonucleotide. PCT document WO 91/06629 discloses oligonucleotides with one or more phosphodiester linkages between adjacent nucleosides replaced by formation of an acetal/ketal type link which is capable of binding to RNA or DNA.
[012] It would be advantageous to provide new nucleosides for therapeutic and diagnostic applications and for inclusion in oligonucleotides. When incorporated into oligonucleotides, it would be advantageous to provide novel oligonucleotides that exhibit different high binding affinity for target molecules and/or show increased resistance to exonucleases and endonucleases than oligonucleotides prepared from naturally occurring nucleosides. It would also be useful to provide nucleotides with modifications that confer biological activity other than, or in addition to, endonuclease and exonuclease resistance. SUMMARY
[013] The present disclosure provides modifications uridines at position 5 of the following general formula:
wherein: R is selected from the group consisting of -(CH2)n-RX1; RX1 is selected from the group consisting of:

*denotes the attachment point of the group RX1 to the connecting group (CH2)n where RX4 is selected from the group consisting of a linear or branched lower (C1-C20) alkyl; halogen (F, Cl, Br, I); nitrile (CN); boronic acid (BO2H2); carboxylic acid (COOH); carboxylic acid ester (COORX2); primary amide (CONH2); secondary amide (CO-NHRX2); tertiary amide (CONRX2RX3); sulfonamide (SO2NH2); N-alkyl sulfonamide (SONHRX2); wherein RX2, RX3 are independently selected from the group consisting of a straight or branched (C1-C20) lower alkyl; phenyl (C6H5); an RX4 substituted phenyl ring (RX4C6H4), where RX4 is defined above; a carboxylic acid (COOH); a carboxylic acid ester (COORX5), wherein RX5 is a straight or branched (C1-C20) lower alkyl; and cycloalkyl, where RX2 = RX3 = (CH2)n; where n = 0-10; wherein X is selected from the group including, but not limited to, -H, -OH, -OMe, -O-allyl, -F, -OEt, -OPr, -OCH2CH2OCH3 and -azido; where R' is selected from the group including, but not limited to, -OAc; -OBz; and -OSiMe2tBu; where R'' is selected from the group including, but not limited to, H, DMT and triphosphate (-P(O)(OH)-OP(O)(OH)-OP(O)(OH)2) or a salt of the same; and carbocyclic sugars, α-anomeric sugars, epimeric sugars such as arabinose, xyloses or lixoses, pyranose sugars, furanose sugars, sedo-heptuloses, acyclic analogues and abasic nucleoside analogues such as methyl riboside. where can
be replaced by carbocyclic sugar analogues, α-anomeric sugars, epimeric sugars such as arabinose, xyloses or lixoses, pyranose sugars, furanose sugars, sedo-heptuloses, acyclic analogues and abasic nucleoside analogues such as methyl riboside.
[014] Included are 3'-phosphoramidite and 5'-triphosphate derivatives of said compounds having the following general formulas, respectively, or salts thereof:
wherein all portions are as defined above.
[015] The compounds of the present disclosure can be incorporated into oligonucleotides or aptamers using standard synthetic or enzymatic methods of preparing such compounds.
[016] Also provided in the present disclosure are methods for producing the compounds of the present disclosure and the compounds produced by means of said methods.
[017] In one embodiment, there is provided a method for preparing a modified C-5 aminocarbonylpyrimidine, said method comprising: reacting a 5-position modified pyrimidine with a trifluoroethoxycarbonyl with an amine in the presence of a base; and isolating said modified C-5 aminocarbonylpyrimidine.
[018] In another embodiment, there is provided a method for preparing a 3'-phosphoramidite from a modified C-5 aminocarbonylpyrimidine, said method comprising: reacting said modified C-5 aminocarbonylpyrimidine with cyanoethyldiisopropyl- chlorophosphoramidite in the presence of a base; and isolating said 3'-phosphoramidite.
[019] In yet another embodiment, there is provided a method for preparing a 5'-triphosphate of a modified C-5 aminocarbonylpyrimidine, said method comprising: a) reacting a modified C-5 aminocarbonylpyrimidine having the formula:
wherein R and X are as defined above, with acetic anhydride in the presence of a base, followed by cleavage of the 5'-DMT group with an acid to form a 3'-acetate of the following structure:
b) carrying out a Ludwig-Eckstein reaction, followed by anion exchange chromatography on the 3'-acetate of step a); and c) isolation of a 5'-triphosphate of a modified C-5 aminocarbonylpyrimidine having the following structure or a salt thereof:
DETAILED DESCRIPTION
[020] Reference will now be made in detail to representative embodiments of the invention. While the invention will be described in conjunction with the enumerated embodiments, it is to be understood that the invention is not intended to be limited to these embodiments. Rather, the invention is intended to encompass all alternatives, modifications and equivalents that may be included within the scope of the present invention as defined by the claims.
[021] Those skilled in the field will recognize many methods and materials similar or equivalent to those described herein, which could be used in and are within the scope of practice of the present disclosure. The present disclosure is by no means limited to the methods and materials described.
[022] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the field to which the present invention belongs. While any methods, devices and materials similar or equivalent to those described herein may be used in practicing or testing the invention, preferred methods, devices and materials are now described.
[023] All publications, published patent documents and patent applications cited in this disclosure are indicative of the level of skill in the art to which the disclosure belongs. All publications, published patent documents and patent applications cited herein are hereby incorporated by reference to the same extent as if each individual publication, published patent document or patent application were specifically and individually indicated to be incorporated by reference.
[024] As used in the present disclosure, including the appended claims, the singular forms "a", "an", "the" and "a" include plural references unless the context clearly dictates otherwise and are used interchangeably with "at least one" and "one or more". Thus, reference to "an aptamer" includes mixtures of aptamers and the like.
[025] As used here, the term "about" represents an insignificant modification or variation of the numerical value so that the basic function of the item to which the numerical value refers is not altered.
[026] The term "each", when used here to refer to a plurality of items, is intended to refer to at least two of the items. It is not necessary that all the items that make up the plurality satisfy an associated additional limitation.
[027] As used herein, the terms "comprises", "comprises", "includes", "including", "contains", "containing" and any variations thereof are intended to encompass a non-exclusive inclusion, so that a process, method, product-by-process or composition of matter comprises, includes or contains an element or list of elements includes not only these elements, but may include other elements not expressly listed or inherent in such process, method, product -by-process or composition of matter.
[028] As used herein, the term "nucleotide" refers to a ribonucleotide or a deoxyribonucleotide or a modified form thereof, as well as an analogue thereof. Nucleotides include species that include purines (eg, adenine, hypoxanthine, guanine and its derivatives and analogues) as well as pyrimidines (eg, cytosine, uracil, thymine and its derivatives and analogues). Compounds
[029] In one embodiment, the present disclosure provides compounds of the following formula:
wherein: R is selected from the group consisting of -(CH2)n-RX1; RX1 is selected from the group consisting of:

*Denotes the attachment point of the group RX1 to the connecting group (CH2)n where RX4 is selected from the group consisting of a linear or branched lower (C1-C20) alkyl; halogen (F, Cl, Br, I); nitrile (CN); boronic acid (BO2H2); carboxylic acid (COOH); carboxylic acid ester (COORX2); primary amide (CONH2); secondary amide (CO-NHRX2); tertiary amide (CONRX2RX3); sulfonamide (SO2NH2); N-alkyl sulfonamide (SONHRX2); wherein RX2, RX3 are independently selected from the group consisting of a straight or branched (C1-C20) lower alkyl; phenyl (C6H5); an RX4 substituted phenyl ring (RX4C6H4), where RX4 is defined above; a carboxylic acid (COOH); a carboxylic acid ester (COORX5), wherein RX5 is a straight or branched (C1-C20) lower alkyl; and cycloalkyl, where RX2 = RX3 = (CH2)n; where n = 0-10; wherein X is selected from the group including, but not limited to, -H, -OH, -OMe, -O-allyl, -F, -OEt, -OPr, -OCH2CH2OCH3 and -azido; where R' is selected from the group including, but not limited to, -OAc; -OBz; and -OSiMe2tBu; where R'' is selected from the group including, but not limited to, H, DMT and triphosphate (-P(O)(OH)-OP(O)(OH)-OP(O)(OH)2) or a salt of the same; and in what
it can be substituted by carbocyclic sugar analogues, α-anomeric sugars, epimeric sugars such as arabinose, xyloses or lixoses, pyranose sugars, fura-nose sugars, sedo-heptuloses, acyclic analogues and abasic nucleoside analogues such as methyl riboside.
[030] In another embodiment, the present disclosure provides compounds of the following formula or salts thereof:
where R, R'' and X are as defined above. Compounds of this general formula are useful for incorporating the modified nucleoside into an oligonucleotide via chemical synthesis.
[031] In still other embodiments, the present disclosure provides compounds of the formula or salts thereof:
where R, R' and X are as defined above. Compounds of this general formula are useful for incorporating the modified nucleoside into an oligonucleotide via enzymatic synthesis.
[032] As used herein, the term "modified C-5 carboxyamideuridine" or "modified C-5 aminocarbonyluridine" refers to a uridine with a carboxycamide modification (-C(O)NH-) at the C-5 position of the uridine including , but without limitation, those portions (R) illustrated above. Examples of modified C-5 carboxycamidauridines include those disclosed in US Patent Nos. 5,719,273 and 5,945,527, as well as, US Provisional Application Serial No. 61/422,957 (the '957 application), filed December 14, 2010 , entitled "Nuclease Resistant Oligonucleotides". Representative modified C-5 pyrimidines include: 5-(N-benzylcarboxycamide)-2'-deoxyuridine (BndU), 5-(N-benzylcarboxycamide)-2'-O-methyluridine, 5-(N-benzylcarboxycamide)-2'- fluorouridine, 5-(N-isobutylcarboxycamide)-2'-deoxyuridine (iBudU), 5-(N-isobutylcarboxycamide)-2'-O-methyluridine, 5-(N-isobutylcarboxycamide)-2'-fluorouridine, 5-(N -tryptaminocarboxycamide)-2'-deoxyuridine (TrpdU), 5-(N-tryptaminocarboxycamide)-2'-O-methyluridine, 5-(N-tryptaminocarboxylicamide)-2'-fluorouridine, 5-(N-[) chloride 1-(3-trimethylammonium)propyl]carboxycamide)-2'-deoxyuridine, 5-(N-naphthylmethylcarboxycamide)-2'-deoxyuridine (NapdU), 5-(N-naphthylmethylcarboxycamide)-2'-O-methyluridine, 5 -(N-naphthylmethylcarboxycamide)-2'-fluorouridine or 5-(N-[1-(2,3-dihydroxypropyl)]carboxycamide)-2'-deoxyuridine).
[033] Specific examples of modified C-5 aminocarbonyluridines, described herein for illustration purposes only, include the following compounds, as well as the 5'-triphosphates and 3'-phosphoramidites and salts thereof of said compounds, as syntheses of which are described in Examples 1-5.
5-(4-Fluorobenzylaminocarbonyl)-2'-deoxyuridine,
5-((R)-2-Furfurylmethylaminocarbonyl)-2'-deoxyuridine,
5-((S)-2-Furfurylmethylaminocarbonyl)-2'-deoxyuridine,
5-(2-(4-Morpholino)ethylaminocarbonyl)-2'-deoxyuridine; and
5-(2-(1-(3-Acetyl-benzimidazolonyl))ethylaminocarbonyl)-2'-deoxyuridine.
[034] Chemical modifications of the modified C-5 uridines described herein may also be combined with, alone or in any combination, sugar modifications at the 2' position, exocyclic amine modifications and 4-thiouridine substitution, and the like. salts
[035] It may be convenient or desirable to prepare, purify and/or manipulate a corresponding salt of the compound, for example a pharmaceutically acceptable salt. Examples of pharmaceutically acceptable salts are discussed in Berge et al. "Pharmaceutically Acceptable Salts" (1977) J. Pharm. Sci. 66: 1-19.
[036] For example, if the compound is anionic or has a functional group which can be anionic (eg -COOH can be -COO-), then a salt can be formed with a suitable cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na+ and K+, alkaline earth cations such as Ca2+ and Mg2+ and other cations such as Al+3. Examples of suitable organic cations include, but are not limited to, ammonium ion (ie, NH4+) and substituted ammonium ions (by x+ x + x + x + example, NH3R , NH2R 2 , NHR 3 , NR 4 ). Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperizine, benzylamine, phenylbenzylamine, choline, meglumine and tromethamine as well as amino acids , such as lysine and arginine. An example of a common quaternary ammonium ion is N(CH3)4+.
[037] If the compound is cationic or has a functional group which can be cationic (eg -NH2 can be -NH3+), then a salt can be formed with a suitable anion. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric and phosphorous.
[038] Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetoxic-benzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethane -sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxyc-naphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulphanilic, tartaric, toluenesulfonic and valeric. Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose.
[039] Unless otherwise specified, a reference to a particular compound also includes salt forms thereof. Preparation of Oligonucleotides
[040] In one aspect, the present disclosure provides methods for using the modified nucleosides described herein, either alone or in combination with other modified nucleosides and/or naturally occurring nucleosides, to prepare modified oligonucleotides. Automated oligodeoxynucleoside synthesis is routine practice in many laboratories (see, for example, Matteucci, MD and Caruthers, MH, (1990) J. Am. Chem. Soc., 103: 3185-3191, the contents of which are hereby incorporated by reference). Synthesis of oligoribonucleosides is also well known (see, for example, Scaringe, S.A., et al., Nucleic Acids Res. 18: 5433-5441 (1990), incorporated herein by reference). As mentioned above, phosphoramidites are useful for incorporating the modified nucleoside into an oligonucleotide via chemical synthesis, and triphosphates are useful for incorporating the modified nucleoside into an oligonucleotide via enzymatic synthesis (see, for example, Vaught, JV et al. (2010) J. Am. Chem. Soc., 132, 4141-4151; Gait, MJ "Oligonucleotide Synthesis, A Practical Approach" (1984) IRL Press (Oxford, UK); Herdewijn, P. "Oligonucleotide Synthesis, A Practical Approach" (1984) IRL Press (Oxford, UK); Synthesis" (2005) (Human Press, Totowa, NJ (each of which is incorporated herein by reference in full).
[041] As used herein, the terms "modify", "modified", "modification" and any variations thereof, when used in reference to an oligonucleotide, mean that at least one of the four constituent nucleotide bases (ie, A , G, T/U and C) of the oligonucleotide is an analog or ester of a naturally occurring nucleotide. In some embodiments, the modified nucleotide refers to the nuclease resistance of the oligonucleotide. Additional modifications can include backbone modifications, methylations, unusual base pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications may also include 3' and 5' modifications, such as capping. Other modifications may include replacement of one or more of the naturally occurring nucleotides by an analogue, internucleotide modifications such as, for example, those with uncharged bonds (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and those with charged bonds (eg, phosphorothioates, phosphorodithioates, etc.), those with intercalators (eg, acridine, psoralen, etc.), those containing chelators (eg, metals, radioactive metals, boron, metals oxidatives, etc.), those containing alkylators and those with modified bonds (eg alpha anomeric nucleic acids, etc.). Furthermore, any of the hydroxyl groups commonly present on the sugar of a nucleotide can be replaced by a phosphonate group or a phosphate group; protected by standard protection groups; or activated to prepare additional bonds to additional nucleotides or a solid support. The terminal 5' and 3' OH groups can be phosphorylated or substituted by amines, organic capping group moieties of about 1 to about 20 carbon atoms, oscillating polyethylene glycol (PEG) polymers, in one embodiment, from about 10 to about 80 kDa, PEG polymers ranging from about 20 to about 60 kDa, in another embodiment, or other hydrophilic or hydrophobic biological or synthetic polymers.
[042] Polynucleotides may also contain analogous forms of ribose or deoxyribose sugars that are generally known in the art, including 2'-O-methyl, 2'-O-allyl, 2'-O-ethyl, 2'-O- propyl, 2'-O-CH2CH2OCH3, 2'-fluoro- or 2'-azido, carbocyclic sugar analogues, a-anomeric sugars, epimeric sugars such as arabinose, xyloses or lixoses, pyranose sugars, furanose sugars, sedo- heptuloses, acyclic analogues and abasic nucleoside analogues such as methyl riboside. As mentioned above, one or more phosphodiester linkages can be replaced by alternative linking groups. These alternative linker groups include modalities in which phosphate is replaced by P(O)S ("thioate"), P(S)S ("dithioate"), (O)NRx2 ("amidate"), P (O) Rx, P(O)ORx', CO or CH2 ("formacetal"), in which each Rx or Rx' is, independently, H or (C1-C20) unsubstituted or optionally substituted alkyl containing an ether linkage (-O-), aryl, alkenyl, cycloalkyl, cycloalkenyl or araldyl. Not all bonds in a polynucleotide need to be identical. Substitution of analogous forms of sugars, purines and pyrimidines can be advantageous in the design of a final product, as can alternative backbone structures, such as a polyamide backbone, for example.
[043] If present, a modification in the nucleotide structure can be conferred before or after assembly of a polymer. A nucleotide sequence can be interrupted by non-nucleotide components. A polynucleotide can be further modified after polymerization, such as by conjugation with a labeling component.
[044] As used herein, "nucleic acid", "oligonucleotide" and "polynucleotide" are used interchangeably to refer to a polymer of nucleotides and include DNA, RNA, DNA/RNA hybrids and modifications of these types of nucleic acids, oligonucleotides and polynucleotides, wherein attachment of the various entities or portions to nucleotide units at any position is included. The terms "polynucleotide", "oligonucleotide" and "nucleic acid" include double and single stranded molecules as well as triple helical molecules. Nucleic acid, oligonucleotide, and polynucleotide are broader terms than the term aptamer, and thus the terms nucleic acid, oligonucleotide, and polynucleotide include nucleotide polymers that are aptamers, but the terms nucleic acid, oligonucleotide, and polynucleotide are not limited to aptamers.
[045] As used herein, the term "at least one nucleotide", when referring to modifications of a nucleic acid, refers to one, several or all of the nucleotides in the nucleic acid, indicating that any or all occurrences of any one or all of A, C, T, G or U in a nucleic acid can be modified or not.
[046] In other aspects, the methods of the present disclosure use the modified nucleosides described herein, either alone or in combination with other modified nucleosides and/or naturally occurring nucleosides, to prepare aptamers and SOMAmers (described below). In specific embodiments, aptamers and SOMAmers are prepared using the general SELEX or enhanced SE-LEX process as described below.
[047] As used herein, "nucleic acid ligand", "aptamer", "SOMAmer" and "clone" are used interchangeably to refer to a non-naturally occurring nucleic acid that has a desirable action on a molecule target. A desirable action includes, but is not limited to, target binding, catalytic target change, reacting with the target in a way that modifies or alters the target or target's functional activity, covalent attachment to the target (as in a suicide inhibitor), and facilitating the reaction between the target and another molecule. In one embodiment, the action is specific binding affinity through a mechanism which is independent of Watson/Crick base pairing or triple helix formation, wherein the aptamer is not a nucleic acid having the physiological function known to be bound. by the target molecule. Aptamers to a given target include nucleic acids that are identified from a candidate mixture of nucleic acids, where the aptamer is a ligand of the target, by a method comprising: (a) contacting the candidate mixture with the target, wherein nucleic acids having an increased affinity for the target relative to other nucleic acids in the candidate mixture can be separated from the remainder of the candidate mixture; (b) separating the affinity-enhanced nucleic acids from the remainder of the candidate mixture; and (c) amplification of nucleic acids with increased affinity to provide a mixture of nucleic acids enriched in ligands whereby aptamers of the target molecule are identified. It is recognized that affinity interactions are a matter of degree; however, in the present context, the "specific binding affinity" of an aptamer for its target means that the aptamer binds to its target generally with a much greater degree of affinity than it binds to other non-target components in a mixture or sample. An "aptamer", "SOMAmer" or "nucleic acid linker" is a set of copies of a type or species of nucleic acid molecule that has a particular nucleotide sequence. An aptamer can include any suitable number of nucleotides. "Aptamers" refers to more than one such set of molecules. Different saptamers can have the same or different numbers of nucleotides. Aptamers can be DNA or RNA and can be single-stranded, double-stranded, or contain double-stranded and triple-stranded regions.
[048] As used herein, a "SOMAmer" or Modified Aptamer with Slow Dissociation Rate refers to an aptamer having improved dissociation rate characteristics. SOMAmers can be generated using the improved SELEX methods described in U.S. Publication No. 20090004667 entitled "Method for Generating Aptamers with Improved Off-Rates.".
[049] As used herein, "protein" is used synonymously for "peptide", "polypeptide" or "peptide fragment". A "purified" polypeptide, protein, peptide or peptide fragment is substantially free of cellular material or other contaminating proteins from the cell, tissue or cell-free source from which the amino acid sequence is obtained or substantially free of chemical precursors or other chemical substances when chemically synthesized. The SELEX Method
[050] The terms "SELEX" and "SELEX process" are used interchangeably herein to refer to a combination of (1) selection of nucleic acids that interact with a target molecule in a desirable manner, eg, binding with high affinity to a protein, with (2) the amplification of those selected nucleic acids. The SELEX process can be used to identify aptamers with high affinity for a specific target molecule or biomarker.
[051] SELEX generally includes preparation of a candidate mixture of nucleic acids, binding of the candidate mixture to the desired target molecule to form an affinity complex, separation of affinity complexes from unbound candidate nucleic acids, if - arrest and isolation of the nucleic acid from the affinity complex, purification of the nucleic acid and identification of a specific aptamer sequence. The process can include multiple cycles to further refine the affinity of the selected aptamer. The process can include amplification steps at one or more points in the process. See, for example, U.S. Patent No. 5,475,096 entitled "Nucleic Acid Ligands". The SELEX process can be used to generate an aptamer that covalently binds to its target, as well as an aptamer that non-covalently binds its target. See, for example, U.S. Patent No. 5,705,337 entitled "Systematic Evolution of Nucleic Acid Ligands by Exponential Enrichment: Chemi-SELEX".
[052] The SELEX process can be used to identify high-affinity aptamers containing modified nucleotides that impart improved characteristics to the aptamer such as, for example, improved in vivo stability or improved distribution characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions. Aptamers identified by the SELEX process containing modified nucleotides are described in US Patent No. 5,660,985 entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides", which describes oligonucleotides containing chemically modified nucleotide derivatives at positions 5 ' and 2' of pyrimidines. US Patent No. 5,580,737, vide supra, describes highly specific aptamers containing one or more nucleotides modified with 2'-amino (2'-NH2), 2'-fluoro (2'-F) and/or 2'- O-methyl (2'-OMe). See also U.S. Patent Application Publication No. 20090098549 entitled "SELEX and PHOTOSELEX", which describes nucleic acid libraries having ex-pandied physical and chemical properties and their use in SELEX and PhotoSELEX.
[053] SELEX can also be used to identify aptamers that have desirable off-rate characteristics. See US Patent Publication No. 20090004667 entitled "Method for Generating Aptamers with Improved Off-Rates", which is incorporated herein by reference in its entirety, describes improved SELEX methods for generating aptamers that can bind to target molecules . Methods for producing aptamers and photoaptamers having lower dissociation rates with their respective target molecules are described. The methods involve contacting the candidate mixture with the target molecule, allowing the formation of target nucleic acid complexes to occur, and performing a slow dissociation rate enrichment process in which target nucleic acid complexes have rapid dissociation rates dissociation and do not form again, whereas complexes with slow dissociation rates remain intact. Additionally, the methods include the use of modified nucleotides in the production of candidate nucleic acid mixtures to generate aptamers with improved off-rate performance (see U.S. Patent Publication No. 20090098549, entitled "SELEX and PhotoSELEX"). (Also see U.S. Patent No. 7,855,054 and U.S. Patent Publication No. 20070166740). Each such application is incorporated herein by reference in its entirety.
[054] "Target" or "target molecule" refers herein to any compound on which a nucleic acid can act in a desirable manner. A target molecule can be a protein, peptide, nucleic acid, carbohydrate, lipid, polysaccharide, glycoprotein, hormone, receptor, antigen, antibody, virus, pathogen, toxic substance, substrate, metabolite, transition state analogue, cofactor, inhibitor, drug, matrix, nutrient, growth factor, cell, tissue, any portion or fragment of any of the foregoing, etc., without limitation. Virtually any chemical or biological effector can be a suitable target. Molecules of any size can serve as targets. A target can also be modified in certain ways to enhance the likelihood or strength of an interaction between the target and the nucleic acid. A target may also include any minimal variation from a particular compound or molecule such as, in the case of a protein, for example, minor variations in amino acid sequence, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation or any other manipulation or modification, such as conjugation with a labeling component, which does not substantially alter the identity of the molecule. A "target molecule" or "target" is a series of copies of a type or species of molecule or multimolecular structure that is capable of binding an aptamer. "Target molecules" or "targets" refers to more than one such set of molecules. Embodiments of the SELEX process in which the target is a peptide are described in U.S. Patent No. 6,376,190 entitled "Modified SELEX Processes Without Purified Protein". Chemical Synthesis
[055] Methods for chemical synthesis of compounds provided in the present disclosure are described here. These and/or other well known methods can be modified and/or adapted in various ways in order to facilitate the synthesis of additional compounds provided in the present disclosure.
[056] Referring to Scheme 1, in one approach, the aminocarbonylpyrimidines modified at position C-5 of the present disclosure are prepared by reacting a pyrimidine modified at position 5 with a trifluoroethoxycarbonyl with an amine in the presence of a base; and isolating said modified C-5 aminocarbonylpyrimidine.
[057] In some embodiments, trifluoroethoxycarbonylpyrimidine is selected from the group of compounds including, but not limited to, compounds having the following structure:
wherein X is selected from the group including, but not limited to, -H, -OH, -OMe, -O-allyl, -F, -OEt, -OPr, -OCH2CH2OCH3 and -azido and where
it can be substituted by carbocyclic sugar analogues, α-anomeric sugars, epimeric sugars such as arabinose, xyloses or lixoses, pyranose sugars, fura-nose sugars, sedo-heptuloses, acyclic analogues and abasic nucleoside analogues such as methyl riboside. In some embodiments, the amine is selected from the group including, but not limited to, compounds of the formula RNH2 where R is selected from the group consisting of -(CH2)n-RX1;
[058] RX1 is selected from the group consisting of:

*denotes the attachment point of the group RX1 to the connecting group (CH2)n where RX4 is selected from the group consisting of a linear or branched lower (C1-C20) alkyl; halogen (F, Cl, Br, I); nitrile (CN); boronic acid (BO2H2); carboxylic acid (COOH); carboxylic acid ester (COORX2); primary amide (CONH2); secondary amide (CO-NHRX2); tertiary amide (CONRX2RX3); sulfonamide (SO2NH2); N-alkyl sulfonamide (SONHRX2); wherein RX2, RX3 are independently selected from the group consisting of a straight or branched (C1-C20) lower alkyl; phenyl (C6H5); an RX4 substituted phenyl ring (RX4C6H4), where RX4 is defined above; a carboxylic acid (COOH); a carboxylic acid ester (COORX5), wherein RX5 is a straight or branched (C1-C20) lower alkyl; and cycloalkyl, where RX2 = RX3 = (CH2)n; where n = 0-10.
[059] In specific modalities, the amine is selected from the group consisting of:

[060] In some embodiments, the base is a tertiary amine selected from the group consisting of triethylamine, diisopropylamine and the like.
[061] Referring to Scheme 1, the present disclosure also provides a method for the synthesis of the 3'-phosphoramidite of a modified C-5 aminocarbonylpyrimidine comprising: reacting said modified C-5 aminocarbonylpyrimidine with cyanoethyldiisopropyl-chlorophosphoramidite in the presence of a base; and isolating said 3'-phosphoramidite. In some embodiments, the modified C-5 aminocarbonylpyrimidine has the following structure:
where R and X are as defined above. In some embodiments, the base is a tertiary amine selected from the group consisting of triethylamine, diisopropylamine, and the like.
[062] Again referring to Scheme 1, the present disclosure also provides a method for the synthesis of a 5'-triphosphate of a modified C-5 aminocarbonylpyrimidine comprising: a) reacting a modified C-5 aminocarbonylpyrimidine having the formula:
wherein R and X are as defined above, with acetic anhydride in the presence of a base, followed by cleavage of the 5'-DMT group with an acid to form a 3'-acetate of the following structure:
b) carrying out a Ludwig-Eckstein reaction, followed by anion exchange chromatography on the 3'-acetate of step a); and c) isolation of a 5'-triphosphate of a modified C-5 aminocarbonylpyrimidine having the following structure or a salt thereof:

[063] The base used is selected from the group including, but not limited to, a tertiary amine. In some embodiments, the base is pyridine. The acid used in step a is selected from the group including, but not limited to, dichloroacetic acid, trichloroacetic acid and 1,1,1,3,3,3-hexafluoro-2-propanol.
[064] In an alternative approach, trifluoroethoxycarbonylpyrimidine has the following structure:

[065] Referring to Scheme 2, this compound is formed by reacting compound (7) of Scheme 2 with carbon monoxide and trifluoroethanol in the presence of a palladium catalyst and a base. The base is selected from the group including, but not limited to, a tertiary amine selected from triethylamine and the like.
[066] The present disclosure includes compounds prepared by each of the methods described above. EXAMPLES
[067] The following examples are provided for illustrative purposes only and are not intended to limit the scope of the invention as defined by the appended claims. All of the examples described here were carried out using standard techniques, which are well known and routine to those skilled in the field. Routine molecular biology techniques described in the examples below can be performed as described in standard laboratory manuals, such as Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (2001).
[068] The following general procedures were employed to produce the modified nucleosides described in Examples 1-3 and 5. The nomenclature used here is based on the system described by Matsuda et al. Nucleic Acids Research 1997, 25: 2784-2791. Scheme 1
Example 1. Synthesis of 5'-O-DMT-dU-5-Carboxamides (3a-e)
[069] 5'-O-Dimethoxytrityl-5-(4-fluorobenzylaminocarbonyl)-2'-deoxyuridine (3a). The starting material, 5'-O-dimethoxytrityl-5-trifluoroethoxycarbonyl-2'-deoxyuridine (1) was prepared by the procedure of Matsuda et al (Nomura, I.; Ueno, I.; Matsuda, A. Nucleic Acids Research 1997, 25: 2784-2791; Ito, T., Ueno, I.; Matsuda, A. Nucleic Acids Research 2003, 31: 2514-2523). A solution of (1) (9.85 g, 15 mmol), 4-fluorobenzylamine (2a) (2.25 g, 18 mmol, 1.3 eq), triethylamine (4.2 mL, 30 mmol) and anhydrous acetonitrile (30 ml) was heated under an inert atmosphere at 60-70°C for 2-24 hours. Quantitative conversion of (1) to the amide (3a) was confirmed by thin layer chromatography (silica gel 60, 5% methanol/dichloromethane) or HPLC. The reaction mixture was concentrated in vacuo and the residue purified by flash chromatography on silica gel (Still, WC; Kahn, M.; Mitra, AJ Org. Chem. 1978, 43: 2923) using an eluent of 0-3% methanol in 1% triethylamine/99% ethyl acetate. Fractions containing pure product were combined and evaporated. Traces of residual solvents were removed by co-evaporation with anhydrous acetonitrile, followed by drying under high vacuum, to provide (3a) as a white solid (6.57 g, 64% yield). 1H-NMR (300 MHz, CD3CN) δ 2.20-2.40 (2H, m), 3.28 (2H, d, J = 4.3 Hz), 3.76 (6H, s), 4, 01 (1H, dd, J = 3.8, 4.2 Hz), 4.26-4.30 (1H, m), 4.48 (2H, bd, J = 6.1 Hz), 6 .11 (1H, t, J = 6.5 Hz), 6.85-7.46 (13H, m), 7.037.36 (4H, m), 8.58 (1H, s), 9. 01 (1H, t, J = 6.1 Hz). MS (m/z) calcd. for C38H36FN3O8, 681.25; found 680.4 [M-H]-.
[070] 5'-O-Dimethoxytrityl-5-((R)-2-furfurylmethylaminocarbonyl)-2'-deoxyuridine (3b). Compound (3b) was prepared as described for (3a) using (R)-2-furfurylmethylamine (2b) and isolated as a white solid (9.3 g, 94%) yield. The eluent for chromatography was 1% triethylamine/4% methanol/95% ethyl acetate. 1H-NMR (CD3CN) δ 1.51-1.57 (1H, m), 1.84-1.94 (3H, m), 2.18-2.38 (2H, m), 3.25- 3.52 (4H, m superimposed), 3.66-3.93 (3H, m superimposed), 3.78 (6H, s), 3.97-4.02 (1H, m), 4.24- 4.29 (1H, m), 6.12 (1H, t, J = 6.5), 6.86-7.47 (13H, m), 8.54 (1H, s), 8.83 (1H, bs). MS (m/z) calcd. for C36H39N3O9, 657.27; found 656.5 [M-H]-.
[071] 5'-O -Dimethoxytrityl-5-((S)-2-furfurylmethylaminocarbonyl)-2'-deoxyuridine (3c). Compound (3c) was prepared as described for (3b) using (S)-2-furfurylmethylamine (2c) and isolated as a white solid (9.9 g, 99% yield). 1H-NMR (CD3CN) δ 1.50-1.59 (1H, m), 1.84-1.95 (3H, m), 2.18-2.40 (2H, m), 3.24- 3.50 (4H, m superimposed), 3.69-3.97 (3H, m superimposed), 3.78 (6H, s), 3.98-4.02 (1H, m), 4.25- 4.30 (1H, m), 6.14 (1H, t, J = 6.5), 6.87-7.47 (13H, m), 8.54 (1H, s), 8.84 (1H, bs). MS (m/z) calcd. for C36H39N3O9, 657.27; found 656.5 [M-H]-.
[072] 5'-O-Dimethoxytrityl-5-(2-(4-morpholino)ethylaminocarbonyl)-2'-deoxyuridine_(3d). Compound (3d) was prepared as described for (3a), using 2-(4-morpholino)-ethylamine (2d) and isolated as a white solid (8.2 g, 80% yield). The eluent for chromatography was 5% methanol/2% triethylamine/93% dichloromethane. 1H-NMR (CD3CN) δ 2.21-2.39 (2H, m), 2.39-2.41 (4H, m), 2.48 (2H, t, J = 6.2 Hz), 3 .27-3.29 (2H, m), 3.41 (2H, dt, J = 5.8, 6.2 Hz), 3.61-3.64 (4H, m), 3.78 (6H , s), 3.98-4.02 (1H, m), 4.25-4.30 (1H, m), 6.10 (1H, t, J = 6.4), 6.86-7 .47 (13H, m), 8.55 (1H, s), 8.79 (1H, bt, J ~ 6 Hz). MS (m/z) calcd. for C37H42N4O9, 686.30; found 685.7 [M-H]-.
[073] 5'-O - Dimethoxytrityl-5-(2-(N-benzimidazolonyl)ethylaminocarbonyl)-2'-deoxyuridine (3e). Compound (3e) was prepared as described for (3a) using N-benzimidazolonyl-2-ethylamine (2e) (CAS RN64928-88-7). The eluent for chromatography was 2% methanol/1% triethylamine/97% dichloromethane. The pure product was isolated as a brown solid (8.2 g, 74.5% yield). 1H-NMR (CD3CN) δ 2.20-2.36 (2H, m), 3.27-3.29 (2H, m), 3.60 (2H, q, J = 6.5 Hz), 3.758 (3H, s), 3.762 (3H, s), 3.97 (2H, t, J = 6.5 Hz), 3.98-4.02 (1H, m), 4.27-4.30 ( 1H, m), 6.09 (1H, t, J = 6.5 Hz), 6.86-7.48 (13H, m), 6.91-7.10 (4H, m), 8.52 (1H, s), 8.76 (1H, t, J = 6.1 Hz). MS (m/z) calcd. for C40H39N5O9, 733.27; found 732.0 [M-H]-. Example 2. Synthesis of 5'-O-DMT-Nucleoside CE-Phosphoramidites (4a-4e)
[074] 5'-O - Dimethoxytrityl-5-(4-fluorobenzylaminocarbonyl)-3'-O -[(2-cyanoethyl)(N,N-diisopropylamino)phosphinyl]-2'-deoxyuridine (4a). A solution of DMT-protected nucleoside (3a) (4.00 g, 5.9 mmol) in anhydrous dichloromethane (40 mL) was cooled to approximately -10°C under an atmosphere of dry argon. Diisopropylethylamine (3.1 mL, 17.6 mmol, 3 eq) was added, followed by dropwise addition of 2-cyanoethyldiisopropylchlorophosphoramidite (1.7 mL, 7.7 mmol, 1.3 eq). The solution was stirred for one hour and complete reaction was confirmed by thin layer chromatography (silica gel 60, ethyl acetate/hexane). The reaction mixture was partitioned between ice-cold 2% sodium bicarbonate solution (200ml) and ethyl acetate (200ml). The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography on silica gel using a mobile phase of 1% triethylamine/99% ethyl acetate. Fractions containing pure product were combined and evaporated in vacuo (<30°C). Traces of residual chromatography solvent were removed by co-evaporation with anhydrous acetonitrile and drying in high vacuum to provide (4a) as a white solid foam (4.10 g, 80% yield). 1H-NMR (CD3CN, two isomers) δ 1.02-1.16 (12H, m), 2.27-2.57 (2H, m), 2.51/2.62 (2H, 2t, J = 6.0/6.0 Hz), 3.25-3.37 (2H, m), 3.50-3.79 (4H, m overlap), 3.738 (3H, s), 3.742 (3H, s) , 4.13/4.16 (1H, 2q, J = 3.5/3.7 Hz), 4.37-4.43 (1H, m), 4.44-4.47 (2H, m) , 6.09/6.10 (1H, 2t, J = 6.4/7.1 Hz), 6.83-7.44 (13H, m), 7.01-7.30 (4H, m) , 8.58/8.60 (1H, 2s), 8.98 (1H, b, J~5.5 Hz), 9.24 (1H, bs). 31 P-NMR (CD3CN) δ 148.01 (s), 148.06 (s). 19F-NMR (CD3CN) δ -117.65 (m). MS (m/z) calcd. for C47H53FN5O9P, 881.36; found 880.3 [M-H]-.
[075] 5'-O-Dimethoxytrityl-5-((R)-2-furfurylmethylaminocarbonyl)-3'-O -[(2-cyanoethyl)(N,N-diisopropylamino)phosphinyl]-2'-deoxyuridine ( 4b). Compound (4b) was prepared as described for (4a). A 1:1 mixture of diastereomeric phosphoramidites was isolated as a white solid foam (3.15 g, 62% yield). The eluent for chromatography was 1% tritetylamine/20% hexanes/79% ethyl acetate. 1H-NMR (CD3CN, two isomers) δ 1.14-1.27 (12H, m), 1.51-1.59 (1H, m), 1.86-1.94 (3H, m), 2 .27-2.59 (2H, m), 2.54/2.65 (2H, 2t, J = 6.0/5.7 Hz), 3.27-3.38 (2H, m), 3 .44-3.97 (9H, m superimposed), 3.782 (3H, s), 3.786 (3H, s), 4.11-4.18 (1H, m), 4.39-4.48 (1H, m), 6.11/6.13 (1H, 2t, J = 5.6/6.1 Hz), 6.96-7.47 (13H, m), 8.58/8.60 (1H, 2s), 8.75 (1H, bt, J~5.4 Hz), 9.36 (1H, bs). 31 P-NMR (CD3CN) δ 148.09 (s), 148.13 (s). MS (m/z) calcd. for C45H56N5O10P, 857.38; found 856.6 [M-H]-.
[076] 5'-O-Dimethoxytrityl-5-((S)-2-furfurylmethylaminocarbonyl)-3'-O-[(2-cyanoethyl)(N,N-diisopropylamino)phosphinyl]-2'-deoxyuridine ( 4c). Compound (4c) was prepared as described for (4b). A 1:1 mixture of diastereomeric phosphoramidites was isolated as a white solid foam (3.74 g, 74% yield). 1H-NMR (CD3CN, two isomers) δ 1.14-1.27 (12H, m), 1.51-1.59 (1H, m), 1.86-1.94 (3H, m), 2 .28-2.51 (2H, m), 2.53/2.65 (2H, 2t, J = 6.0/6.0 Hz), 3.25-3.41 (2H, m), 3 .44-4.14 (9H, m superimposed), 3.783 (3H, s), 3.786 (3H, s), 4.12-4.19 (1H, m), 4.40-4.49 (1H, m), 6.11/6.13 (1H, 2t, J = 6.3/6.3 Hz), 6.86-7.48 (13H, m), 8.58/8.60 (1H, 2s), 8.75 (1H, bt, J~5.4 Hz), 9.36 (1H, bs). 31 P-NMR (CD3CN) δ 148.09 (s), 148.13 (s). MS (m/z) calcd. for C45H56N5O10P, 857.38; found 856.5 [M-H]-.
[077] 5'-O - Dimethoxytrityl-5-(2-(4-morpholino)ethylaminocarbonyl)-3'-O - [(2-cyanoethyl)(N,N-diisopropylamino)phosphinyl]-2'-deoxyuridine (4d). Compound (4d) was prepared as described for (4a), except that purification used a chromatography eluent of 1% triethylamine/5% anhydrous ethanol/94% ethyl acetate. The 1:1 mixture of diastereomeric phosphoramidites was isolated as a white solid foam (3.9 g, 75% yield). 1H-NMR (CD3CN, two isomers) δ 1.04-1.19 (12H, m), 2.28-2.59 (2H, m), 2.43-2.47 (6H, m superimposed ), 2.53/2.64 (2H, 2t, J = 6.2/6.2 Hz), 3.27-3.76 (8H, m superimposed), 3.61-3.65 (4H, m), 3.781 (3H, s), 3.789 (3H, s), 4.12-4.19 (1H, m), 4.39-4.49 (1H, m), 6.11/6.13 (1H, 2t, J = 5.2//5.2), 6.86-7.48 (13H, m), 8.58/8.60 (1H, 2s), 8.78 (1H, bt , J~5.3 Hz), 9.78 (1H, bs). 31 P-NMR (CD3CN) δ 148.08 (s), 148.11 (s). MS (m/z) calcd. for C46H59N6O10P, 886.4; found 885.7 [M-H]-.
[078] 5'-O-Dimethoxytrityl-5-(2-(N-benzimidazolonyl)ethylaminocarbonyl)-3'-O-[(2-cyanoethyl)(N,N-diisopropylamino)phosphinyl]-2' -deoxyuridine (4e). Compound (4e) was prepared as described for (4a), except that purification used a chromatography eluent of 1% triethylamine/10% anhydrous methanol/89% ethyl acetate. The 1:1 mixture of diastereomeric phosphoramidites was isolated as a white solid foam (1.6 g, 31% yield). 1H-NMR (CD3CN, two isomers) δ 1.03-1.18 (12H, m), 2.27-2.57 (2H, m), 2.52/2.63 (2H, 2t, J = 6.0/6.0), 3.27-3.37 (2H, m), 3.49-3.80 (6H, m superimposed), 3.732 (3H, s), 3.735/3.738 (3H , 2s), 4.00 (2H, bt, J~6.0 Hz), 4.12-4.18 (1H, m), 4.30-4.47 (1H, m), 6.08/ 6.10 (1H, 2t, J = 6.3/6.3 Hz), 6.85-7.48 (13H, m), 6.93-7.09 (4H, m), 8.57/ 8.60 (1H, 2s), 8.82/8.83 (1H, 2bt, J~4.3/4.3 Hz), 9.48 (1H, bs). 31 P-NMR (CD3CN) δ 148.07 (s), 148.10 (s). Example 3. Synthesis of 3'-O-Acetyl-Nucleosides (5a-5e) 5-(4-Fluorobenzylaminocarbonyl)-3'-O-acetyl-2-deoxyuridine(5a).
[079] The nucleoside (3a) (3.00 g, 4.4 mmoles) was dissolved in a solution of anhydrous pyridine (30 ml) and acetic anhydride (3 ml). The solution was stirred overnight and concentrated in vacuo to provide the 3'-O-acetyl nucleoside. Residual solvent was removed by co-evaporation with anhydrous toluene (10 ml). The residue was dissolved in anhydrous dichloromethane (10ml) and treated with 3% trichloroacetic acid in dichloromethane (58ml). The red solution was stirred overnight, during which time the product crystallized. The slurry was cooled to -20°C, filtered and washed with diethyl ether. The residue was dried in vacuo to provide (5a) as a grayish solid (1.10 g, 59% yield). 1H-NMR (CD3CN) δ 2.07 (3H, s), 2.33-2.38 (1H, m), 2.50-2.52 (1H, m), 3.63-3.64 ( 2H, m), 4.10 (1H, bdd, J = 3.1, 5.1 Hz), 4.46 (2H, d, J = 6.0 Hz), 5.19-5.26 (2 H, m superimposed), 6.15 (1H, t, J = 7.0 Hz), 7.15 (2H, tt, J = 2.2, 9.0 Hz), 7.31-7.38 ( 2H, m), 8.79 (1H, s), 9.14 (1H, bt, J = 6.1 Hz), 11.95 (1H, bs). 19 F-NMR (CD3CN) δ - 116.02 (tt, J = 5.5, 9.0 Hz)). MS (m/z) calcd. for C19H20FN3O7, 421.13; found 419.8 [MH]-. 5-((R)-2-Furfurylmethylaminocarbonyl)-3'-O-acetyl-2'-deoxyuridine(5b).

[080] The compound (5b) was prepared from (4b) by the procedure described for (5a) and isolated by precipitation from a mixture of dichloromethane and ethyl acetate as a white solid (1, 27 g, 73 % yield. 1H-NMR (CDCl3) δ 1.57-2.02 (4H, m), 2.12 (3H, s), 2.46-2.50 (2H, m), 3.03 (1H, bs) , 3.43-3.64 (2H, m), 3.75-3.97 (2H, m), 3.78-4.10 (3H, m), 4.20-4.21 (1H, m), m), 5.40-5.42 (1H, m), 6.35 (1H, dd, J = 6.5, 7.7 Hz), 8.91 (1H, t, J = 5.5 Hz ), 9.17 (1H, s), 9.44 (1H, bs). MS (m/z) calcd. for C17H23N3O8, 397.15; found 396.1 [MH]-. 5-((S)-2-Furfurylmethylaminocarbonyl)-3'-O-acetyl-2'-deoxyuridine(5c).

[081] Compound (5c) was prepared from (4c) by the procedure described for (5a) and isolated by precipitation from a mixture of dichloromethane and diethyl ether as a pale orange solid (1, 35 g, 77% yield. 1 H-NMR (CDCl 3 ) δ 1.57-2.03 (4H, m), 2.12 (3H, s), 2.47-2.51 (2H, m), 2.98 (1H, bs) , 3.40-3.68 (2H, m), 3.78-3.95 (2H, m), 3.90-4.12 (3H, m), 4.20-4.21 (1H, m), m), 5.395.42 (1H, m), 6.33 (1H, dd, J = 6.7, 7.4 Hz), 8.90 (1H, t, J = 5.5 Hz), 9, 15 (1H, s), 9.37 (1H, bs). MS (m/z) calcd. for C17H23N3O8, 397.15; found 395.9 [MH]-. 5-(2-(4-Morpholino)ethylaminocarbonyl)-3'-O-acetyl-2-deoxyuridine(5d).

[082] The nucleoside (3d) (1.00 g, 1.37 mmol) was dissolved in a solution of anhydrous pyridine (10 ml) and acetic anhydride (1 ml). The solution was stirred overnight and concentrated in vacuo to provide the 3'-O-acetyl nucleoside. Residual solvent was removed by co-evaporation with anhydrous toluene (10 ml). The residue was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (20 ml) (Leonard, NJ Tetrahedron Letters, 1995, 36: 7833) and heated to approximately 50°C for 3 hours. Complete cleavage of the DMT group was confirmed by TLC. The mixed red solution was dissipated by pouring into well-stirred methanol (200 mL). The resulting yellow solution was concentrated in vacuo and the residue dissolved in hot ethyl acetate (20ml). The product crystallized on cooling and the resulting slurry was aged at -20°C, followed by filtration and washing with ethyl acetate. The 3'-O-acetyl nucleoside (5d) was isolated as a white solid (0.46 g, 79% yield). 1H-NMR (DMSO-d6) δ 2.07 (3H, s), 2.32-2.45 (7H, m overlap), 2.49-2.52 (1H, m), 3.33-3 .40 (2H, m), 3.57 (4H, t, J = 4.5 Hz), 3.60-3.63 (2H, m), 4.09 (1H, bdd, J = 3.2 , 5.2 Hz), 5.17-5.25 (2H, m), 6.14 (1H, t, J = 7.0 Hz), 8.74 (1H, s), 8.89 (1H , bt, J = 5.4 Hz), 11.90 (1H, bs). MS (m/z) calcd. for C18H26N4O8, 426.18; found 425.0 [MH]-. 5-(2-(1-(3-Acetyl-benzimidazolonyl))ethylaminocarbonyl)-3'-O-acetyl-2'-deoxyuridine(5e).

[083] Compound (5e) was prepared as described for (5d), except that the product crystallized directly when the DMT cleavage reaction was poured into methanol. Diacetyl nucleoside (5e) was isolated by filtration as a white solid (0.55 g, 78% yield). 1H-NMR (DMSO-d6) δ 2.07 (3H, s), 2.30-2.37 (1H, m), 2.49-2.52 (1H, m), 2.63 (3H, s) 3.33 (1H, bs), 3.55-3.64 (4H, m superimposed), 3.99 (2H, t, J = 6.4 Hz), 4.09 (1H, bdd, J = 2.3, 5.2 Hz), 5.15-5.25 (2H, m), 6.13 (1H, dd, J = 6.3, 7.6 Hz), 7.11 (1H, ddd, J = 1.2, 7.6, 7.9 Hz), 7.22 (1H, ddd, J = 1.2, 7.6, 7.9 Hz), 7.33 (1H, dd, J = 0.8, 7.9 Hz), 8.02 (1H, dd, J = 0.8, 8.0 Hz), 8.05 (1H, bs), 8.83 (1H, bt), 8.71 (1H, s), 11.87 (1H, bs). MS (m/z) calcd. for C23H25N5O9, 515.17; found 513.9 [M-H]-. Example 4. Alternative Synthesis of 3'-O-Acetyl-Nucleosides (5a-5d)
[084] The 3'-O-acetyl-nucleosides (5a-d) were also synthesized through an alternative pathway (Scheme 2) from the starting material, 3'-O-acetyl-5'-O-dimethoxytrityl -5-iodo-2'-deoxyuridine (7) (Vaught, JD, Bock, C., Carter, J., Fitzwater, T., Otis, M., Schneider, D., Rolando, J., Waugh, S. ., Wilcox, SK, Eaton, BEJ Am. Chem. Soc. 2010, 132, 4141-4151). Briefly, referring to Scheme 2, palladium(III) catalyzed trifluoroethoxycarbonylation of the iodide provided the activated ester intermediate (8). Condensation of (8) with the amines (2a-d) (1.3 eq., triethylamine (3 eq), acetonitrile, 60-70°C, 2-24 hours), followed by cleavage of the 5'-protecting group O-DMT (3% trichloroacetic acid/dichloromethane or 1,1,1,3,3,3-hexafluoro-2-propanol, room temperature) provided (5a-d), identical to the products produced via the intermediates (3a -d) (Scheme 1). Scheme 2


[085] 3'-O-Acetyl-5'-O-dimethoxytrityl-5-(2,2,2-trifluoroethoxycarbonyl)-2'-deoxyuridine(8). A 500 mL heavy-walled glass pressure reactor was filled with argon and charged with 3'-O-acetyl-5'-O-dimethoxytrityl-5-iodo-2'-deoxyuridine (7) (15.9 g, 22.8 mmoles), anhydrous acetonitrile (200 mL), triethylamine (7.6 mL, 54.7 mmol) and 2,2,2-trifluoroethanol (16.4 mL, 228 mmol). The resulting solution was vigorously stirred and degassed by evacuation to <100 mmHg for 2 minutes. The flask was filled with argon and bis(benzonitrile)dichloropalladium(II) (175 mg, 0.46 mmol) was added. The resulting yellow solution was again degassed and then filled with carbon monoxide (99.9%) (Caution: Poisonous Gas!) from a gas bypass. A pressure of 1-10 psi of CO was maintained while the reaction mixture was vigorously stirred and heated to 60-65°C for 12 hours. The cooled reaction mixture was filtered (Caution: Poisonous Gas) to remove black precipitate and concentrated in vacuo. The orange residue was partitioned with dichloromethane (120ml) and 10% sodium bicarbonate (80ml). The organic layer was washed with water (40ml) and dried over sodium sulphate, filtered and concentrated to leave an orange foam (17g). This crude product could be used as is or further purified by flash chromatography on silica gel with an eluent of 30% hexane/1% triethylamine/69% ethyl acetate to provide (8) as a colorless solid foam (12.7 g, 80% yield). 1H-NMR (CD3CN)) δ 2.03 (3H, s), 2.37-2.56 (2H, m), 3.36-3.38 (2H, m), 3.78 (6H, s ), 4.15-4.19 (1H, m), 4.37-4.55 (2H, m), 5.21-5.26 (1H, m), 6.09 (1H, t, J = 6.1 Hz), 6.84-7.46 (13H, m), 8.53 (1H, s). 19F-NMR (CD3CN) δ -74.07 (t, J = 8.8 Hz). MS (m/z) calcd. for C35H33F3N2O10, 698.21; found 697.4 [M-H]-. Example 5. Synthesis of Nucleoside 5'-O-Triphosphates
[086] 5-(4-Fluorobenzylaminocarbonyl)-2'-deoxyuridine-5'-O-triphosphate (tris-triethylammonium salt) (6a). Triphosphate (6a) was synthesized from 3'-O-acetyl nucleoside (5a) by the procedure of Ludwig and Eckstein (Ludwig, J. and Eckstein, FJ Org. Chem. 1989, 54: 631) in a 500 μmol (5x) scale. The crude triphosphate product, after ammonolysis and evaporation, was purified by anion exchange chromatography as described in the General Procedure (below).
[087] General Procedure for Anion Exchange HPLC Purification of Nucleoside Triphosphates. Nucleoside triphosphates were purified via anion exchange chromatography using an HPLC column packed with Source Q resin (GE Healthcare), installed over a preparative HPLC system, with detection at 278 nm. The linear elution gradient employed two buffers (buffer A: 10 mM triethylammonium bicarbonate/10% acetonitrile and buffer B: 1M triethylammonium bicarbonate/10% acetonitrile), with the gradient running at low-content room temperature of buffer B to high content of buffer B during the course of the elution. The desired product was typically the final material to elute from the column and was observed as a broad peak spanning a retention time of approximately ten to twelve minutes (early eluting products included a variety of reaction by-products, the most significant being the nucleoside diphosphate). Several fractions were collected during product elution. The fraction was analyzed by reverse phase HPLC on a Waters 2795 HPLC with a Waters Simmetry column (PN: WAT054215). Fractions containing pure product (typically >90%) were evaporated in a Genevac VC 3000D evaporator to provide light brown to colorless resins. Fractions were reconstituted in deionized water and pooled for final analysis. Product quantification was performed by analysis using a Hewlett Packard 8452A Diode Array Spectrophotometer at 278 nm. Product yields were calculated via the equation A = εCL, where A is the UV absorbance, ε is the estimated extinction coefficient and L is the path length (1 cm).
[088] The crude product (6a) was dissolved in approximately 5 ml of buffer A (Table 1: Prep-HPLC conditions 1). Each purification injection consisted of an approximately 1 mL filtered aliquot of this solution injected onto a Waters 625 HPLC with a 486 detector fitted with a 6 mL Resource Q column (GE Healthcare Product Code: 17-1179-01) with a mobile phase gradient from 0%-100% buffer B in a 50 minute elution at 12 mL/minute. For (6a) [ε est. 13.700 cm-1 M-1], the isolated purified product was 130 µmol (26% yield). 1H-NMR (D2O) δα 1.15 (27H, t, J = 7.3 Hz), 2.32-2.37 (2H, m), 3.07 (18H, q, J = 7.3 Hz ), 4.06-4.17 (3H, m superimposed), 4.42 (2H, bd, J~0.7 Hz), 4.49-4.53 (1H, m), 4.70 (> 7H, bs, HOD), 6.12 (1H, t, J = 6.8 Hz), 6.96-7.26 (4H, m), 8.45 (1H, s). 19F-NMR (D2O) δ -116.18 (m). 31 P-NMR (D2O) δ -10.58 (d, J = 20 Hz), -11.45 (d, J = 20 Hz), -23.29 (t, J = 20 Hz). MS (m/z) calcd. for C17H21FN3O15P3, 619.02; found 618.0 [MH]-. Table 1. Prep-HPLC Conditions 1


[089] 5-((R)-2-Furfurylmethylaminocarbonyl)-2'-deoxyuridine-5'-O - triphosphate (tris-triethylammonium salt)(6b). Triphosphate (6b) was synthesized from 3'-O-acetyl-nucleoside (5b) as described for (6a). The crude product (6b) was purified in a single injection on a Waters 2767 preparatory system with a Waters 2489 detector using a Waters AP-5 column (Waters PN: WAT023331, 50mm x 100mm) packed with 196 ml of Source 15Q resin. (GE Healthcare Product Code: 17-0947-05). The same buffers as above were used, but the elution gradient was changed to 25% to 80% Buffer B in a 90 minute elution at 50 mL/minute (Table 2: Prep-HPLC Conditions 2). A second purification was performed on a C18 HPLC column to remove residual impurities (Table 4: Prep-HPLC conditions 4). For (6b) [ε est. 10.200 cm-1 M-1], the purified isolated product was 325 µmol (65% yield). 1H-NMR (D2O) δα 1.17 (27H, t, J = 7.3 Hz), 1.49-1.63 (1H, m), 1.77-2.02 (3H, m), 2 .34-2.39 (2H, m), 2.85-3.83 (5H, m superimposed), 3.08 (18H, q, J = 7.3 Hz), 4.01-4.19 ( 3H, m overlap), 4.52-4.56 (1H, m), 4.70 (>7H, bs, HOD), 6.15 (1H, t, J = 6.8 Hz), 8.48 (1H, s). 31 P-NMR (D2O) δ -10.50 (d, J = 20 Hz), -11.51 (d, J = 20 Hz), -23.25 (t, J = 20 Hz). MS (m/z) calcd. for C15H24FN3O16P3, 595.04; found 594.1 [MH]-. Table 2. Prep-HPLC Conditions 2

[090] 5-((S)-2-Furfurylmethylaminocarbonyl)-2'-deoxyuridine-5'-O-triphosphate (tris-triethylammonium salt)(6c). Triphosphate (6c) was synthesized from 3'-O-acetyl-nucleoside (5c) as described for (6a). The crude product (6c) was purified in a single injection on a Waters 2767 preparatory system with a Waters 2489 detector using a Waters AP-5 column (Waters PN: WAT023331, 50mm x 100mm) packed with 196 ml 15Q resin resin (GE Healthcare Product Code: 17-0947-05). The same buffers as above were used, but the elution gradient was changed to 25% to 80% Buffer B in a 90 minute elution at 50 mL/minute (Table 2: Prep-HPLC Conditions 2). A second purification was carried out on a C18 HPLC column to remove residual impurities (Table 4: prep-HPLC conditions 4). For (6c) [ε est. 10.200 cm-1 M-1], the isolated purified product was 255 µmol (yield 51%). 1H-NMR (D2O) δα 1.17 (27H, t, J = 7.3 Hz), 1.49-1.63 (1H, m), 1.78-2.01 (3H, m), 2 .34-2.39 (2H, m), 2.85-3.82 (5H, m superimposed), 3.09 (18H, q, J = 7.3 Hz), 4.01-4.19 ( 3H, m overlap), 4.52-4.56 (1H, m), 4.70 (>7H, bs, HOD), 6.15 (1H, t, J = 6.7 Hz), 8.48 (1H, s). 31 P-NMR (D2O) δ -10.60 (d, J = 20 Hz), -11.42 (d, J = 20 Hz), -23.25 (t, J = 20 Hz). MS (m/z) calcd. for C15H24FN3O16P3, 595.04; found 594.1 [M-H]-.
[091] 5-(2-(4-Morpholino)ethylaminocarbonyl)-2'-deoxyuridine-5'-O - triphosphate (bis-triethylammonium salt)(6d). Triphosphate (6d) was synthesized from 3'-O-acetyl-nucleoside (5d) as described for (6a). The crude product (6d) was purified with the same equipment and buffers as used for (6a), but the gradient was modified to pass 15% to 60% buffer B during the 50 minute elution to improve product decomposition (Table 3: Prep-HPLC conditions 3). For (6d) [ε est. 10.200 cm-1 M-1], the isolated purified product was 54 µmol (yield 11%). 1H-NMR (D2O) δD 1.17 (18H, t, J = 7.3 Hz), 2.37-2.41 (2H, m), 2.91-2.98 (2H, m), 3 .09 (12H, q, J = 7.3 Hz), 3.203.27 (4H, m), 3.87-3.90 (4H, m), 3.63-3.68 (2H, m), 4.10-4.18 (3H, m overlapping), 4.56-4.60 (1H, m), 4.70 (>7H, bs, HOD), 6.15 (1H, bt, J = 6 .3 Hz), 8.48 (1H, s). 31 P-NMR (D2O) δ -9.99 (d, J = 21 Hz), -11.90 (d, J = 20 Hz), -23.19 (t, J = 20 Hz). MS (m/z) calcd. for C16H27N4O16P3, 624.06; found 623.1 [MH]-. Table 3. Prep-HPLC Conditions 3
Table 4. Prep-HPLC Conditions 4

[092] 5-(2-(N-Benzimidazolonyl)ethylaminocarbonyl)-2'-deoxyuridine-5'-O-triphosphate (bis-triethylammonium salt)(6e). Triphosphate (6e) was synthesized from 3'-O-acetyl-nucleoside (5e) as described for (6a). The crude product (6e) was purified with the same equipment and buffers as used for (6a), but the gradient was modified to pass 15% to 60% buffer B during the 50 minute elution to improve product decomposition (Table 3: Prep-HPLC conditions 3). For (6e) [ε est. 13.700 cm-1 M-1], the purified isolated product was 101 µmol (20% yield). 1H-NMR (D2O) δα 1.17 (18H, t, J = 7.3 Hz), 2.17-2.36 (2H, m), 3.09 (12H, q, J = 7.3 Hz ), 3.60-3.73 (2H, m), 4.01 (2H, t, J = 5.4 Hz), 4.03-4.15 (3H, m), 4.45-4, 50 (1H, m), 4.70 (>7H, bs, HOD), 6.04 (1H, t, J = 6.6 Hz), 6.95-7.12 (4H, m), 8. 02 (1H, s). 31 P-NMR (D2O) δ -10.35 (d, J = 20 Hz), -11.40 (d, J = 20 Hz), - 23.23 (t, J = 20 Hz). MS (m/z) calcd. for C19H24N5O16P3, 671.04; found 670.1 [M-H]-.
[093] The foregoing modalities and examples are intended to be exemplary only. No particular embodiment, example or element of a particular embodiment or example shall be construed as a critical, required or essential element or feature of any of the claims. Furthermore, no element described herein is required to practice the appended claims, unless expressly described as "essential" or "critical". Various changes, modifications, substitutions and other variations may be made in the disclosed embodiments without deviate from the scope of the present invention, which is defined by the appended claims. The descriptive report, including the examples, is to be considered in an illustrative rather than a restrictive manner and all such modifications and substitutions are intended to be included within the scope of the invention. Accordingly, the scope of the invention will be determined by the appended claims and their legal equivalents, rather than by the examples provided above. For example, steps mentioned in any of the method or process claims may be carried out in any feasible order and are not limited to the order presented in any of the embodiments, examples or claims.

权利要求:
Claims (3)
[0001]
1. Composite, characterized by the fact that it has the following structure:
[0002]
2. Compound according to claim 1, characterized in that it has the following structure:
[0003]
3. Compound, according to claim 1, characterized in that it has the following structure:

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP6352324B2|2018-07-04|5-position modified pyrimidine and its use

---

CN105658658B|2019-11-05|Cytidine-5-formyl amine-modified polynucleotide composition and its correlation technique

---

AU2013202528B2|2015-07-30|5-position modified pyrimidines and their use

---

TWI541249B|2016-07-11|5-position modified pyrimidines and their use

---

JP7025818B2|2022-02-25|5-position modified pyrimidine and its use

---

BR122021003805B1|2021-10-13|MODIFIED PYRIMIDINES IN POSITION 5

同族专利:

---

公开号 | 公开日

---

SG2014006522A|2014-03-28|

---

ES2610159T3|2017-04-26|

---

TWI505833B|2015-11-01|

---

CN102985435B|2016-10-26|

---

MX2012011779A|2012-12-17|

---

US20110275794A1|2011-11-10|

---

CN102858990B|2016-08-03|

---

IL222339D0|2012-12-31|

---

TWI593701B|2017-08-01|

---

EP2558478B1|2018-03-07|

---

EP2558586A1|2013-02-20|

---

JP5901610B2|2016-04-13|

---

WO2011130289A1|2011-10-20|

---

TW201900668A|2019-01-01|

---

JP2016145230A|2016-08-12|

---

HK1252803A1|2019-06-06|

---

JP6012591B2|2016-10-26|

---

MY160608A|2017-03-15|

---

KR20180030229A|2018-03-21|

---

NZ602618A|2013-12-20|

---

IL256013A|2018-05-31|

---

EP2558586B1|2016-10-12|

---

SG184497A1|2012-11-29|

---

IL256014A|2018-05-31|

---

CA3066785A1|2011-10-20|

---

CN102985435A|2013-03-20|

---

SG184089A1|2012-11-29|

---

AR081452A1|2012-09-05|

---

CN107033204A|2017-08-11|

---

EP2558478A4|2013-10-23|

---

US9163056B2|2015-10-20|

---

KR20190018750A|2019-02-25|

---

US8598140B2|2013-12-03|

---

JP2018109050A|2018-07-12|

---

EP3345915B1|2021-11-24|

---

JP2013523887A|2013-06-17|

---

TW202019943A|2020-06-01|

---

TWI643864B|2018-12-11|

---

US20190233461A1|2019-08-01|

---

AU2011240677A1|2012-11-01|

---

CA2793451A1|2011-10-20|

---

MX2012011771A|2012-12-17|

---

BR112012025872A2|2016-10-18|

---

IL252703D0|2017-08-31|

---

CO6630139A2|2013-03-01|

---

KR20130103317A|2013-09-23|

---

CN104069512A|2014-10-01|

---

TW201134482A|2011-10-16|

---

KR20130043099A|2013-04-29|

---

EA201291034A1|2013-04-30|

---

KR102185779B1|2020-12-03|

---

EP3345915A1|2018-07-11|

---

TWI684596B|2020-02-11|

---

KR101952671B1|2019-02-27|

---

KR101842269B1|2018-03-26|

---

JP6352324B2|2018-07-04|

---

ES2667491T3|2018-05-11|

---

CA2797188C|2020-03-31|

---

HK1201740A1|2015-09-11|

---

US20180127450A1|2018-05-10|

---

IL222339A|2015-11-30|

---

UA105290C2|2014-04-25|

---

US20140058076A1|2014-02-27|

---

US20150376223A1|2015-12-31|

---

TW201936623A|2019-09-16|

---

JP2013523177A|2013-06-17|

---

BR112012025872B8|2021-05-25|

---

EA022429B1|2015-12-30|

---

IL256014D0|2018-01-31|

---

US10221207B2|2019-03-05|

---

DK2558478T3|2018-05-22|

---

IL242038D0|2015-11-30|

---

TW201730198A|2017-09-01|

---

AU2011240774B2|2014-04-10|

---

US20160355540A1|2016-12-08|

---

IL242038A|2017-07-31|

---

EP2558478A1|2013-02-20|

---

IL252703A|2017-12-31|

---

AU2011240677B2|2015-05-14|

---

WO2011130195A1|2011-10-20|

---

US20130012693A1|2013-01-10|

---

TWI671309B|2019-09-11|

---

AU2011240774A1|2012-10-18|

---

NO2558478T3|2018-08-04|

---

CA2797188A1|2011-10-20|

---

EP2558586A4|2014-10-15|

---

TW201629079A|2016-08-16|

---

IL256013D0|2018-01-31|

---

CN102858990A|2013-01-02|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4267171A|1979-07-02|1981-05-12|The Regents Of The University Of California|C-5 Substituted cytosine nucleosides|

---

US4415732A|1981-03-27|1983-11-15|University Patents, Inc.|Phosphoramidite compounds and processes|

---

US4711955A|1981-04-17|1987-12-08|Yale University|Modified nucleotides and methods of preparing and using same|

---

US5023243A|1981-10-23|1991-06-11|Molecular Biosystems, Inc.|Oligonucleotide therapeutic agent and method of making same|

---

US4594339A|1982-04-06|1986-06-10|Sloan-Kettering Institute For Cancer Research|Anti-herpes virus compositions containing 5-substituted 1-2'pyrimedene nucleosides|

---

US5599720A|1982-08-27|1997-02-04|Multilyte Limited|Measurement of analyte concentration|

---

US4948882A|1983-02-22|1990-08-14|Syngene, Inc.|Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis|

---

DE3329892A1|1983-08-18|1985-03-07|Köster, Hubert, Prof. Dr., 2000 Hamburg|METHOD FOR PRODUCING OLIGONUCLEOTIDES|

---

US4828979A|1984-11-08|1989-05-09|Life Technologies, Inc.|Nucleotide analogs for nucleic acid labeling and detection|

---

US4737453A|1984-12-12|1988-04-12|Immunomedics, Inc.|Sandwich immunoassay utilizing a separation specific binding substance|

---

EP0229046B1|1985-03-30|1994-05-04|BALLIVET, Marc|Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique|

---

US5093232A|1985-12-11|1992-03-03|Chiron Corporation|Nucleic acid probes|

---

US4752566A|1985-12-17|1988-06-21|Genetics Institute, Inc.|Displacement polynucleotide method and reagent complex employing labeled probe polynucleotide|

---

US5047519A|1986-07-02|1991-09-10|E. I. Du Pont De Nemours And Company|Alkynylamino-nucleotides|

---

US5118672A|1989-07-10|1992-06-02|University Of Georgia Research Foundation|5'-diphosphohexose nucleoside pharmaceutical compositions|

---

US4997818A|1987-09-21|1991-03-05|The University Hospital|Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas|

---

SE8802173D0|1988-06-10|1988-06-10|Astra Ab|PYRIMIDINE DERIVATIVES|

---

JPH05500799A|1989-06-05|1993-02-18|

---

US5134066A|1989-08-29|1992-07-28|Monsanto Company|Improved probes using nucleosides containing 3-dezauracil analogs|

---

AT139255T|1989-10-24|1996-06-15|Gilead Sciences Inc|OLIGONUCLEOTID ANALOGUE WITH NEW BINDINGS|

---

EP0521923B1|1990-03-13|1995-03-08|Acic Inc.|Process for producing nucleosides, and analogs therof|

---

EP0537299A1|1990-03-29|1993-04-21|Gilead Sciences, Inc.|Oligonucleotide-transport agent disulfide conjugates|

---

US6030776A|1990-06-11|2000-02-29|Nexstar Pharmaceuticals, Inc.|Parallel SELEX|

---

US5476766A|1990-06-11|1995-12-19|Nexstar Pharmaceuticals, Inc.|Ligands of thrombin|

---

US5270163A|1990-06-11|1993-12-14|University Research Corporation|Methods for identifying nucleic acid ligands|

---

US6346611B1|1990-06-11|2002-02-12|Gilead Sciences, Inc.|High affinity TGfβ nucleic acid ligands and inhibitors|

---

US5580737A|1990-06-11|1996-12-03|Nexstar Pharmaceuticals, Inc.|High-affinity nucleic acid ligands that discriminate between theophylline and caffeine|

---

US5496938A|1990-06-11|1996-03-05|Nexstar Pharmaceuticals, Inc.|Nucleic acid ligands to HIV-RT and HIV-1 rev|

---

US20030054360A1|1999-01-19|2003-03-20|Larry Gold|Method and apparatus for the automated generation of nucleic acid ligands|

---

KR970002255B1|1990-06-11|1997-02-26|넥스스타 파아마슈티컬드, 인크.|Nucleic acid ligands|

---

US5705337A|1990-06-11|1998-01-06|Nexstar Pharmaceuticals, Inc.|Systematic evolution of ligands by exponential enrichment: chemi-SELEX|

---

US5567588A|1990-06-11|1996-10-22|University Research Corporation|Systematic evolution of ligands by exponential enrichment: Solution SELEX|

---

US5660985A|1990-06-11|1997-08-26|Nexstar Pharmaceuticals, Inc.|High affinity nucleic acid ligands containing modified nucleotides|

---

US5138045A|1990-07-27|1992-08-11|Isis Pharmaceuticals|Polyamine conjugated oligonucleotides|

---

IE920561A1|1991-02-21|1992-08-26|Gilead Sciences|Aptamer specific for thrombin and methods of use|

---

US5840867A|1991-02-21|1998-11-24|Gilead Sciences, Inc.|Aptamer analogs specific for biomolecules|

---

IE920562A1|1991-02-21|1992-08-26|Gilead Sciences|Aptamer specific for biomolecules and method of making|

---

US5582981A|1991-08-14|1996-12-10|Gilead Sciences, Inc.|Method for identifying an oligonucleotide aptamer specific for a target|

---

JP3739785B2|1991-11-26|2006-01-25|アイシスファーマシューティカルズ，インコーポレイティド|Enhanced triple and double helix shaping using oligomers containing modified pyrimidines|

---

US5412087A|1992-04-24|1995-05-02|Affymax Technologies N.V.|Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces|

---

US5719273A|1993-06-14|1998-02-17|Nexstar Pharmaceuticals, Inc.|Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide|

---

US5428149A|1993-06-14|1995-06-27|Washington State University Research Foundation|Method for palladium catalyzed carbon-carbon coulping and products|

---

US5580972A|1993-06-14|1996-12-03|Nexstar Pharmaceuticals, Inc.|Purine nucleoside modifications by palladium catalyzed methods|

---

JP4899014B2|1995-06-02|2012-03-21|イーシー・テクノロジー・エルエルシー|Palladium-catalyzed nucleoside modification method using nucleophiles and carbon monoxide|

---

US5801154A|1993-10-18|1998-09-01|Isis Pharmaceuticals, Inc.|Antisense oligonucleotide modulation of multidrug resistance-associated protein|

---

US5596091A|1994-03-18|1997-01-21|The Regents Of The University Of California|Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides|

---

US5658738A|1994-05-31|1997-08-19|Becton Dickinson And Company|Bi-directional oligonucleotides that bind thrombin|

---

US5945527A|1996-05-30|1999-08-31|Nexstar Pharmaceuticals, Inc.|Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide|

---

AU730154B2|1995-10-27|2001-03-01|Elliot R. Ramberg|Methods and compositions for detection of specific nucleotide sequences|

---

US5861254A|1997-01-31|1999-01-19|Nexstar Pharmaceuticals, Inc.|Flow cell SELEX|

---

US6794499B2|1997-09-12|2004-09-21|Exiqon A/S|Oligonucleotide analogues|

---

US20070166741A1|1998-12-14|2007-07-19|Somalogic, Incorporated|Multiplexed analyses of test samples|

---

US6020483A|1998-09-25|2000-02-01|Nexstar Pharmaceuticals, Inc.|Nucleoside modifications by palladium catalyzed methods|

---

US6175001B1|1998-10-16|2001-01-16|The Scripps Research Institute|Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same|

---

US6734172B2|1998-11-18|2004-05-11|Pacific Northwest Research Institute|Surface receptor antigen vaccines|

---

US7855054B2|2007-01-16|2010-12-21|Somalogic, Inc.|Multiplexed analyses of test samples|

---

US8975026B2|2007-01-16|2015-03-10|Somalogic, Inc.|Method for generating aptamers with improved off-rates|

---

US20110136099A1|2007-01-16|2011-06-09|Somalogic, Inc.|Multiplexed Analyses of Test Samples|

---

US7947447B2|2007-01-16|2011-05-24|Somalogic, Inc.|Method for generating aptamers with improved off-rates|

---

US20040120891A1|1998-12-21|2004-06-24|Craig Hill|Compounds for intracellular delivery of therapeutic moieties to nerve cells|

---

JP3485023B2|1999-05-20|2004-01-13|東亞合成株式会社|Nucleoside compound|

---

EP1284741B1|2000-04-13|2008-11-19|Pharmasset, Inc.|3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections|

---

US6376190B1|2000-09-22|2002-04-23|Somalogic, Inc.|Modified SELEX processes without purified protein|

---

WO2003031591A2|2001-10-10|2003-04-17|Superarray Bioscience Corporation|Detecting targets by unique identifier nucleotide tags|

---

WO2003070984A1|2002-02-15|2003-08-28|Somalogic, Inc.|Methods and reagents for detecting target binding by nucleic acid ligands|

---

JP3978187B2|2002-03-19|2007-09-19|富士通株式会社|Functional molecule and production method thereof|

---

US7767803B2|2002-06-18|2010-08-03|Archemix Corp.|Stabilized aptamers to PSMA and their use as prostate cancer therapeutics|

---

CA2407825A1|2002-10-11|2004-04-11|Andrew J. Simmonds|Trap-tagging: a novel method for the identification and purification of rna-protein complexes|

---

WO2004063342A2|2003-01-09|2004-07-29|Invitrogen Corporation|Cellular delivery and activation polypeptide-nucleic acid complexes|

---

JP4119976B2|2003-02-07|2008-07-16|国立大学法人群馬大学|5-substituted pyrimidine deoxynucleotide derivative and method for synthesizing nucleic acid using the same|

---

US7329742B2|2003-09-04|2008-02-12|The Regents Of The University Of California|Aptamers and methods for their in vitro selection and uses thereof|

---

EP1584923A3|2004-04-07|2006-01-04|Roche Diagnostics GmbH|Stabilization of biomolecules in samples|

---

CA2562151C|2004-04-30|2016-09-06|Alnylam Pharmaceuticals, Inc.|Oligonucleotides comprising a c5-modified pyrimidine|

---

JP2006117542A|2004-10-19|2006-05-11|Pias Arise Kk|Nerve growth factor production inhibitor and external preparation for skin, cosmetic, quasi medicine, itch prophylactic and therapeutic agent and atopic dermatitis therapeutic agent mixed with the nerve growth factor production inhibitor|

---

WO2006063717A2|2004-12-16|2006-06-22|Febit Biotech Gmbh|Polymerase-independent analysis of the sequence of polynucleotides|

---

WO2007044427A2|2005-10-05|2007-04-19|Panomics, Inc.|Detection of nucleic acids from whole blood|

---

JP5256578B2|2005-12-20|2013-08-07|大正製薬株式会社|Preventive or therapeutic agent for pruritic skin disease|

---

KR101149688B1|2006-01-17|2012-05-24|소마로직, 인크.|Multiplexed analyses of test samples|

---

JP5372737B2|2006-03-13|2013-12-18|オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー|Combination therapy using EGFR kinase inhibitors and agents that sensitize tumor cells to the effects of EGFR kinase inhibitors|

---

EP1897886A1|2006-09-08|2008-03-12|Bayer Schering Pharma Aktiengesellschaft|Compounds as aptamer-dimers and their uses in diagnosis and therapy|

---

US8242258B2|2006-12-03|2012-08-14|Agilent Technologies, Inc.|Protecting groups for RNA synthesis|

---

CA2673029C|2006-12-22|2017-03-28|Archemix Corp.|Materials and methods for the generation of transcripts comprising modified nucleotides|

---

US8404830B2|2007-07-17|2013-03-26|Somalogic, Inc.|Method for generating aptamers with improved off-rates|

---

US8703416B2|2008-07-17|2014-04-22|Somalogic, Inc.|Method for purification and identification of sperm cells|

---

WO2008104408A2|2007-02-27|2008-09-04|K. U. Leuven Research & Development|Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents|

---

WO2008137776A2|2007-05-02|2008-11-13|Sirna Therapeutics, Inc.|Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase gene expression using short interfering nucleic acid |

---

WO2009012420A1|2007-07-17|2009-01-22|Somalogic, Inc.|Multiplexed analyses of test samples|

---

US20090215050A1|2008-02-22|2009-08-27|Robert Delmar Jenison|Systems and methods for point-of-care amplification and detection of polynucleotides|

---

EP2354225B1|2008-09-24|2015-04-22|Ribomic Inc.|Aptamer for ngf and use thereof|

---

EP2542266A4|2010-03-03|2013-10-23|Somalogic Inc|Aptamers to 4-1bb and their use in treating diseases and disorders|

---

IN2012KN03036A|2010-03-24|2015-04-10|Ribomic Inc|

---

RU2615143C2|2010-03-24|2017-04-04|Адвирна|Self-delivered rnai compounds of reduced size|

---

WO2011130065A1|2010-04-12|2011-10-20|Merck Sharp & Dohme Corp.|RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID |

---

BR112012025872B8|2010-04-12|2021-05-25|Somalogic Inc|primidins modified at 5-position|

---

JP5995855B2|2010-11-05|2016-09-21|ミラゲン セラピューティクス，インコーポレイテッド|Base-modified oligonucleotide|

---

ES2742284T3|2012-03-28|2020-02-13|Somalogic Inc|Aptamers against PDGF and VEGF and their use in the treatment of conditions mediated by PDGF and VEGF|

---

BR112016010165A2|2013-11-21|2017-12-05|Somalogic Inc|cytidine-5-carboxamide modified nucleotide compositions and methods related thereto|JPH0151312B2|1982-11-17|1989-11-02|Fujitsu Ltd|

---

US20110136099A1|2007-01-16|2011-06-09|Somalogic, Inc.|Multiplexed Analyses of Test Samples|

---

US7947447B2|2007-01-16|2011-05-24|Somalogic, Inc.|Method for generating aptamers with improved off-rates|

---

US8975026B2|2007-01-16|2015-03-10|Somalogic, Inc.|Method for generating aptamers with improved off-rates|

---

US8404830B2|2007-07-17|2013-03-26|Somalogic, Inc.|Method for generating aptamers with improved off-rates|

---

BR112012025872B8|2010-04-12|2021-05-25|Somalogic Inc|primidins modified at 5-position|

---

JP5995855B2|2010-11-05|2016-09-21|ミラゲン セラピューティクス，インコーポレイテッド|Base-modified oligonucleotide|

---

US11214610B2|2010-12-01|2022-01-04|H. Lundbeck A/S|High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |

---

US9539324B2|2010-12-01|2017-01-10|Alderbio Holdings, Llc|Methods of preventing inflammation and treating pain using anti-NGF compositions|

---

KR102025848B1|2010-12-01|2019-11-05|앨더바이오 홀딩스 엘엘씨|Anti-ngf compositions and use thereof|

---

US9078878B2|2010-12-01|2015-07-14|Alderbio Holdings Llc|Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75|

---

US9884909B2|2010-12-01|2018-02-06|Alderbio Holdings Llc|Anti-NGF compositions and use thereof|

---

US9067988B2|2010-12-01|2015-06-30|Alderbio Holdings Llc|Methods of preventing or treating pain using anti-NGF antibodies|

---

ES2742284T3|2012-03-28|2020-02-13|Somalogic Inc|Aptamers against PDGF and VEGF and their use in the treatment of conditions mediated by PDGF and VEGF|

---

EP2836608A4|2012-04-13|2016-02-24|Somalogic Inc|Tuberculosis biomarkers and uses thereof|

---

CN104411825B|2012-07-02|2018-07-20|蔚山科学技术院|Periostin aptamers and anti-cancer composition comprising it|

---

BR112015009138A2|2012-10-23|2020-10-20|Caris Life Sciences Switzerland Holdings, S.A.R.L.|methods for characterizing cancer|

---

US10942184B2|2012-10-23|2021-03-09|Caris Science, Inc.|Aptamers and uses thereof|

---

AU2013361323B2|2012-12-19|2018-09-06|Caris Science, Inc.|Compositions and methods for aptamer screening|

---

SG11201507335QA|2013-03-14|2015-10-29|Somalogic Inc|Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions|

---

TWI594975B|2013-04-24|2017-08-11|第一三共股份有限公司|Compound having di-carboxylic moiety|

---

WO2014177510A2|2013-05-03|2014-11-06|Creabilis Sa|Polymer conjugates of indolocarbazole compounds in the treatment of pruritus|

---

GB201312295D0|2013-07-09|2013-08-21|Syntaxin Ltd|Suppression of itch|

---

CA2920508A1|2013-09-09|2015-03-12|Somalogic, Inc.|Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders|

---

AU2014326975B2|2013-09-24|2020-05-07|Somalogic Operating Co., Inc.|Multiaptamer target detection|

---

JP2015062364A|2013-09-25|2015-04-09|Ｎｅｃソリューションイノベータ株式会社|Nucleic acid molecule bound to clenbuterol and application thereof|

---

JP2015062365A|2013-09-25|2015-04-09|Ｎｅｃソリューションイノベータ株式会社|Nucleic acid molecule bound to ractopamine and application thereof|

---

WO2015066001A1|2013-10-29|2015-05-07|Albert Einstein College Of Medicine Of Yeshiva University|Nucleic acid-scaffolded small molecule libraries|

---

BR112016010165A2|2013-11-21|2017-12-05|Somalogic Inc|cytidine-5-carboxamide modified nucleotide compositions and methods related thereto|

---

EP3124611B1|2014-03-24|2019-11-06|Ribomic Inc.|Aptamer for fgf2 and use thereof|

---

NO2718257T3|2014-05-30|2018-04-14|

---

AU2015306683B2|2014-08-25|2021-11-25|Societe Des Produits Nestle S.A.|Egg protein formulations and methods of manufacture thereof|

---

CN104561013A|2015-01-05|2015-04-29|中国人民解放军南京军区福州总医院|Method for optimizing aptamer sequence based on high-throughput sequencing technology|

---

US10588900B2|2016-02-09|2020-03-17|Pharmakea, Inc.|Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof|

---

CN108779140A|2016-03-14|2018-11-09|私募蛋白质体公司|For synthesizing the Compounds and methods for for 5--2 '-uracil deoxyriboside phosphoramidates being incorporated in nucleic acid sequence|

---

CN107663220B|2016-07-27|2020-10-02|上海伯豪医学检验所有限公司|Modified bases, nucleic acids comprising modified bases, aptamers, and uses thereof|

---

US11028395B2|2016-10-24|2021-06-08|Biois Co., Ltd.|TNF-alpha-binding aptamer, and therapeutic use for same|

---

CN108299518A|2018-02-02|2018-07-20|王成宇|A kind of synthetic method of 2`- deoxidations-β-uridine|

---

US20210198672A1|2018-02-12|2021-07-01|Aptacure Therapeutics Limited|Aptamer for sclerostin and use thereof|

---

EP3942295A1|2019-03-22|2022-01-26|Somalogic, Inc.|Reducing intersample analyte variability in complex biological matrices|

---

WO2020236544A1|2019-05-17|2020-11-26|Somalogic, Inc.|Controlling intersample analyte variability in complex biological matrices|

---

US20210390705A1|2020-06-11|2021-12-16|Nautilus Biotechnology, Inc.|Methods and systems for computational decoding of biological, chemical, and physical entities|

---

CN113481204A|2021-07-02|2021-10-08|湖南赛奥维生物技术有限公司|Aptamer of protein, derivative and application thereof|

法律状态:
2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2020-06-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2020-11-17| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2020-12-08| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-03-09| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-04-20| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/04/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |

---

2021-05-25| B16C| Correction of notification of the grant [chapter 16.3 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/04/2011 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |

优先权:

---

申请号 | 申请日 | 专利标题

---

US32314510P| true| 2010-04-12|2010-04-12|

---

US61/323,145|2010-04-12|

---

PCT/US2011/032143|WO2011130289A1|2010-04-12|2011-04-12|5-position modified pyrimidines and their use|

---